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Abstract
Background: Glioblastoma is the deadliest and most prevalent brain tumor. Dexamethasone
(DXM) is a commonly used steroid for treating glioblastoma patients for alleviation of vasogenic
edema and pain prior to treatment with chemotherapeutic drugs. Temozolomide (TMZ), an
alkylating agent, has recently been introduced in clinical trials for treating glioblastoma. Here, we
evaluated the modulatory effect of DXM on TMZ induced apoptosis in human glioblastoma U87MG
cells.
Results: Freshly grown cells were treated with different doses of DXM or TMZ for 6 h followed
by incubation in a drug-free medium for 48 h. Wright staining and ApopTag assay showed no
apoptosis in cells treated with 40 µM DXM but considerable amounts of apoptosis in cells treated
with 100 µM TMZ. Apoptosis in TMZ treated cells was associated with an increase in intracellular
free [Ca2+], as determined by fura-2 assay. Western blot analyses showed alternations in the levels
of Bax (pro-apoptotic) and Bcl-2 (anti-apoptotic) proteins resulting in increased Bax:Bcl-2 ratio in
TMZ treated cells. Western blot analyses also detected overexpression of calpain and caspase-3,
which cleaved 270 kD α-spectrin at specific sites for generation of 145 and 120 kD spectrin break
down products (SBDPs), respectively. However, 1-h pretreatment of cells with 40 µM DXM
dramatically decreased TMZ induced apoptosis, decreasing Bax:Bcl-2 ratio and SBDPs.
Conclusion: Our results revealed an antagonistic effect of DXM on TMZ induced apoptosis in
human glioblastoma U87MG cells, implying that treatment of glioblastoma patients with DXM prior
to chemotherapy with TMZ might result in an undesirable clinical outcome.
Background
Glioblastoma patients usually receive steroids for allevia-
tion of vasogenic edema and pain prior to treatment with
chemotherapeutic drugs. Steroids, however, may modu-
late the sensitivity of tumor cells to chemotherapeutic
drugs. Dexamethasone (DXM), a synthetic glucocorticoid,
is commonly used to reduce inflammation and pain asso-
ciated with glioblastoma [1]. However, DXM has been
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reported to make human glioblastoma cells resistant to
ionizing radiation and chemotherapeutic agents that oth-
erwise cause DNA damage [2-5]. Execution of cells by
apoptosis usually requires the activation of cysteine pro-
teases such as calpains and caspases [6]. Diverse stimuli
may cause an increase in intracellular free [Ca2+], which is
absolutely required for activation of calpain [7]. Activa-
tion of caspases may occur via different mechanisms [8,9].
Mitochondria mediated pathway of apoptosis may be
activated in course of cell death. This involves the regula-
tion of apoptosis by the Bcl-2 family proteins via control-
ling the release of cytochrome c  from mitochondria
[10,11], and subsequent formation of the cytosolic 'apop-
tosome' complex [12,13], which ultimately activates cas-
pase-3 for execution of cells. Thus, the members of the
Bcl-2 family modulate the mitochondrial pathway of
apoptosis [14]. The pro-apoptotic (e.g., Bax, Bcl-xS) and
anti-apoptotic (e.g., Bcl-2, Bcl-xL) members of this family,
respectively, promote and inhibit the translocation of
cytochrome c from mitochondria to cytosol [15].
Glucocorticoids are steroid hormones, which are secreted
in response to stress and can modulate the ability of cells
to undergo apoptosis [16]. For example, glucocorticoids
induce apoptosis in thymocytes [17] and also increase the
sensitivity of hippocampal neurons to cell death [18]. In
contrast, DXM has been reported to induce resistance to
certain drugs in glioblastoma cell lines [3-5]. Although an
association with p21WAF1/CIP1 protein accumulation has
been reported [19], the exact mechanism of DXM medi-
ated protection of glioblastoma cells from apoptosis is
still largely unclarified. Exposure of human astrocytoma
D384 and rat glioblastoma C6 cells to staurosporine
induced apoptosis but pretreatment of those cells with
DXM caused reduction in staurosporine mediated apop-
tosis [20]. In addition, DXM also conferred protection
against the induction of apoptosis by anti-cancer agents
including camtothecin and etoposide [20]. It has also
been shown that exposure of glioblastoma cells to gluco-
corticoids induces partial resistance to anti-cancer agents
such as cisplatinum, methotrexate, vincristine, cytarabine,
adriamycin, and teniposide [3-5]. DXM appears to inter-
fere with p53-dependent pathways of drug toxicity since
the glioblastoma cell lines (LN-229 and U87MG) with
wild-type p53 status were protected from drug toxicity by
DXM to a greater extent than the cell lines (LN-18, LN-
308, and T98G) with mutant p53 [3-5]. It has been
reported earlier that DXM mediated protection from can-
cer chemotherapy occurs via a p53-independent pathway
of regulating p21WAF1/CIP1 expression in glioblastoma cells
but this effect appears to be cell-type specific [19]. Thus,
there remains a concern of modulatory effects of DXM on
the mechanism of action of any chemotherapeutic agent
for treatment of glioblastoma. Therefore, we have initi-
ated this investigation to examine the modulatory effect
of DXM on temozolomide (TMZ) induced apoptosis of
glioblastoma cells. In an in vitro model using the human
glioblastoma U87MG cells, we have investigated whether
DXM confers resistance to TMZ action via inhibition of
apoptosis.
TMZ is an alkylating chemotherapeutic drug that readily
crosses the blood-brain-barrier in glioblastoma patients
[21]. It is chemically related to decarbazine and is the 3-
methyl derivative of the experimental anti-cancer drug
mitozolomide. It has shown anti-tumor activity and rela-
tively low toxicity in Phase I and Phase II clinical trials in
patients with various advanced cancers, including malig-
nant glioblastomas [21]. TMZ is spontaneously hydro-
lyzed under physiological conditions to its active
metabolite 5-(3-methyltriazen-1-yl) imidazole-4-carbox-
amide (MTIC) [22]. The mechanism of action of MTIC is
proposed to be methylation of DNA at the O6 position of
guanine, with an additional methylation at its N7 position
[23,24]. However, O6-methylguanine (O6-meG) may be
removed by O6-methylguanine methyl transferase
(MGMT) [25]. Cells deficient in MGMT do not repair O6-
meG. Replication of DNA introduces a T instead of C
opposite to O6-meG, resulting in GT mismatches [26].
Activation of mismatch repair system (MMRS) may
remove T during DNA repair synthesis. However, ineffec-
tive MMRS causes growth arrest and eventually apoptotic
death [27]. These studies have helped define the action of
TMZ in cancer cells of mostly hemopoietic origin. How-
ever, the action of TMZ in glioblastoma cells remains
largely undefined. Glioblastomas are relatively resistant to
anti-cancer agents that cause apoptosis via DNA alkyla-
tion. Therefore, we have investigated the mechanism of
TMZ induced apoptosis in human glioblastoma U87MG
cells.
We found that TMZ caused apoptosis in U87MG cells as
detected by morphological and biochemical assays. Alter-
ations in the levels of pro-apoptotic Bax and anti-apop-
totic Bcl-2 proteins are known to regulate the
commitment to apoptosis [14,15]. Therefore, we investi-
gated the levels of these apoptosis regulatory proteins fol-
lowing treatment of U87MG cells with TMZ. The
initiation of apoptosis in U87MG cells following exposure
to TMZ requires activation of calpain, a Ca2+-dependent
cysteine protease, which plays a role in the mechanism of
cell death in human malignant brain tumors including
glioblastoma [28]. Besides, caspase-3 activity was also
increased in TMZ induced apoptosis in U87MG cells. Pre-
treatment of U87MG cells with DXM blocked TMZ
induced apoptosis, indicating that DXM worked as an
antagonistic agent in TMZ induced apoptosis in human
glioblastoma cells. The knowledge gained from our inves-
tigation implies that the combination of DXM and TMZ
for the treatment of human glioblastoma patient mayMolecular Cancer 2004, 3:36 http://www.molecular-cancer.com/content/3/1/36
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result in an undesirable clinical outcome. Preliminary
results of this investigation have previously been pre-
sented [29].
Results
Evaluation of viability and apoptotic death both 
morphologically and biochemically
Exclusion of trypan blue dye by viable U87MG cells was
evaluated under a light microscope using a hemocytome-
ter after all treatments. A pretreatment with DXM pre-
vented decrease in cell viability (panel A, Fig. 1).
Morphological features of apoptosis were detected follow-
ing Wright staining (panel B, Fig. 1) and counted to deter-
mine the amount of apoptotic cell death (panel C, Fig. 1)
based on characteristic morphological features such as
condensation of the nucleus and cytoplasm, cytoplasmic
blebbing, and the formation of apoptotic bodies. All treat-
ment groups were examined under the light microscopy
and cells were counted to determine the percentage of
apoptotic cells (panel C, Fig. 1). Compared to control
(CTL) cells, cells treated with 100 µM TMZ showed an
increase in the percentage of apoptotic cells (P < 0.001). A
pretreatment of cells with 40 µM DXM decreased TMZ
induced apoptosis by three-fold, compared to treatment
of cells with TMZ only.
Results obtained from Wright staining were further sup-
ported by the ApopTag assay (panel A, Fig. 2). Both CTL
and DXM treated cells showed little or no brown color,
confirming almost absence of ApopTag positive cells or
apoptosis. The percentage of ApopTag positive cells was
calculated (panel B, Fig. 2) and found to be highly signif-
icant (P < 0.001) in TMZ treated cells, compared to CTL
cells. A pretreatment of cells with DXM considerably
attenuated apoptotic DNA fragmentation in TMZ treated
cells.
Treatment with TMZ increased intracellular free [Ca2+]
Using fura-2 assay, intracellular free [Ca2+] was deter-
mined in all treatment groups (Fig. 3). No significant dif-
ference (P = 0.928) was seen between CTL cells and cells
treated with DXM alone. Cells treated with TMZ showed a
significant increase (P = 0.007) in intracellular free [Ca2+],
compared to CTL cells. This increase was attenuated
almost 100% by a pretreatment of the cells with DXM.
There was no significant difference (P = 0.999) between
intracellular free [Ca2+] in CTL cells and those treated with
DXM plus TMZ.
TMZ induced apoptosis with an increase in Bax:Bcl-2 ratio
A commitment to apoptosis was measured by examining
any increase in the ratio of Bax (pro-apoptotic protein)
expression to Bcl-2 (anti-apoptotic protein) expression.
The bax gene encodes different isoforms. The antibody we
used in this investigation could recognize 21 kD Baxα and
Determination of apoptosis based on morphological features Figure 1
Determination of apoptosis based on morphological 
features. Four treatment groups: control (CTL); 40 µM 
dexamethasone (DXM) for 8 h; 100 µM temozolomide 
(TMZ) for 6 h; pretreatment with 40 µM DXM for 2 h fol-
lowed by 100 µM TMZ for 6 h. (A) DXM prevented TMZ 
mediated decrease in U87MG cell viability. The trypan blue 
exclusion assay was used to assess cell viability in U87MG 
cells. (B) Photomicrographs showing representative cells 
from each treatment group. The arrows indicate apoptotic 
cells. (C) Bar graphs indicating the percentage of apoptotic 
cells counted from each group. Significant difference between 
CTL and TMZ treated cells was indicated by * (P ≤ 0.05) and 
significant difference between TMZ treated cells and DXM 
plus TMZ treated cells was indicated by # (P ≤ 0.05).Molecular Cancer 2004, 3:36 http://www.molecular-cancer.com/content/3/1/36
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24 kD Baxβ bands (panel A, Fig. 4). Here, we considered
both bands in our estimation of total Bax expression. We
also examined the level of Bcl-2 expression in all treat-
ment groups (panel B, Fig. 4). Almost same level of β-actin
expression in each treatment ensured that equal amount
of protein was loaded in each lane (panel C, Fig. 4). Based
on the Western blot experiments (panels A and B, Fig. 4),
the Bax:Bcl-2 ratios were measured in all treatment groups
(panel D, Fig. 4). There was no significant difference (P =
0.983) in Bax:Bcl-2 ratio between CTL and DXM treated
cells (panel D, Fig. 4). Compared to CTL cells, a rise in
Bax:Bcl-2 ratio (panel D, Fig. 4) in cells exposed to TMZ
was influenced more by a change in Bax expression (panel
A, Fig. 4) than a change in Bcl-2 expression (panel B, Fig.
4). Compared to CTL cells, cells treated with TMZ showed
a significant increase (P = 0.007) in the Bax:Bcl-2 ratio
(panel D, Fig. 4). There was a significant difference (P =
0.019) in Bax:Bcl-2 ratio between cells treated with TMZ
ApopTag assay for detection and determination of DNA  fragmentation in U87MG cells Figure 2
ApopTag assay for detection and determination of 
DNA fragmentation in U87MG cells. Four treatment 
groups: control (CTL); 40 µM dexamethasone (DXM) for 8 
h; 100 µM temozolomide (TMZ) for 6 h; pretreatment with 
40 µM DXM for 2 h followed by 100 µM TMZ for 6 h. (A) 
The photomicrographs showing representative cells from 
each treatment group. The arrows indicate apoptotic cells. 
(B) Bar graphs indicating the average percentage of apoptotic 
cells counted from each group. Significant difference between 
CTL and TMZ treated cells was indicated by * (P ≤ 0.05) and 
significant difference between TMZ treated cells and DXM 
plus TMZ treated cells was indicated by # (P ≤ 0.05).
Bar graphs indicating percentage of increase of intracellular  free [Ca2+] using fura-2 Figure 3
Bar graphs indicating percentage of increase of intra-
cellular free [Ca2+] using fura-2. These data were gener-
ated from U87MG cells grown in phenol red-free medium 
for 24 h prior to treatments with the drugs in freshly pre-
pared phenol red-free medium. Four treatment groups: con-
trol (CTL); 40 µM dexamethasone (DXM) for 8 h; 100 µM 
temozolomide (TMZ) for 6 h; pretreatment with 40 µM 
DXM for 2 h followed by 100 µM TMZ for 6 h. Percent 
changes in intracellular free [Ca2+] were shown at nM levels. 
Significant difference between CTL and TMZ treated cells 
was indicated by * (P ≤ 0.05) and significant difference 
between TMZ treated cells and DXM plus TMZ treated cells 
was indicated by # (P ≤ 0.05).Molecular Cancer 2004, 3:36 http://www.molecular-cancer.com/content/3/1/36
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alone and those treated with DXM plus TMZ, indicating a
loss of commitment to apoptosis due to a pretreatment
with DXM. There was no significant difference (P = 0.871)
in Bax:Bcl-2 ratio between CTL cells and cells pretreated
with DXM and then treated with TMZ.
Calpain and caspase-3 activities as determined by α-
spectrin degradation
Calpain and caspase-3 activities were assessed by Western
blot analysis of the calpain-specific 145 kD SBDP and the
caspase-3-specific 120 kD SBDP, respectively (panel A,
Fig. 5). Level of β-actin expression, which was almost uni-
form in all treatments, was used as a loading control
(panel B, Fig. 5). There was no significant difference (P =
0.911) between CTL cells and DXM treated cells in gener-
ation of 145 kD SBDP, indicating similar levels of calpain
activity in these two cases (panel C, Fig. 5). The generation
of 145 kD SBDP in cells treated with TMZ was about 1.5-
fold more intense (P = 0.003) than CTL cells, indicating
that the level of calpain activity was increased in cells due
to treatment with TMZ. Cells pretreated with DXM and
then treated with TMZ showed a significant decrease in
the generation of 145 kD SBDP, indicating an inhibitory
effect of DXM on TMZ mediated increase in calpain activ-
ity (panel C, Fig. 5).
Caspase-3 activity was also measured by Western blot
analysis in the generation of caspase-3-specific 120 kD
SBDP (panel D, Fig. 5). Compared to CTL cells, treatment
of cells with DXM alone did not cause a significant change
(P = 0.983) in caspase-3 activity. Caspase-3 activity in cells
treated with TMZ was almost 1.5 times more (P = 0.001)
than CTL cells (panel D, Fig. 5). Thus, pretreatment of
cells with DXM prior to treatment with TMZ appeared to
decrease the upregulation of caspase-3 activity. Further-
more, there was no significant difference (P  = 0.785)
between CTL cells and cells that were pretreated with
DXM and then treated with TMZ (panel D, Fig. 5).
Caspase-3 activation as determined by generation of 
caspase-3-p20 fragment
Caspase-3 activation was also measured by Western blot
analysis of the production of active 20 kD caspase-3
fragment (panel A, Fig. 6). Again, almost uniform expres-
sion of β-actin in all treatments served as an internal
standard and indicated equal amounts of protein loadings
in all lanes (panel B, Fig. 6). The intensities of active 20 kD
caspase-3 band were almost similar in CTL cells and cells
treated with DXM alone (panel C, Fig. 6). Treatment of
cells with DXM alone did not cause a significant change (P
= 0.613) in caspase-3 activation over CTL cells. But there
was a significant increase (P = 0.001) in production of
active 20 kD caspase-3 fragment in cells treated with TMZ,
compared to CTL cells. Treatment of cells with DXM prior
to TMZ appeared to significantly decrease the activation of
caspase-3 (panel C, Fig. 6), indicating an inhibitory effect
of DXM on TMZ induced caspase-3 activation.
Discussion
Our studies indicated that pretreatment of human gliob-
lastoma U87MG cells with DXM did not support chemo-
therapeutic action of TMZ. Treatment of U87MG cells
with TMZ induced apoptosis (Figs. 1 and 2) to a signifi-
cant extent by increasing intracellular free [Ca2+] (Fig. 3),
interfering with the expression of apoptosis regulatory
proteins of the Bcl-2 family resulting in upregulation of
Bax:Bcl-2 ratio (Fig. 4), and increasing the activities of cal-
pain and caspase-3 (Figs. 5 and 6). But a pretreatment of
the cells with DXM prevented all these pro-apoptotic
The Bax:Bcl-2 ratio measured by Western blot analysis Figure 4
The Bax:Bcl-2 ratio measured by Western blot analy-
sis. Four treatment groups: control (CTL); 40 µM dexameth-
asone (DXM) for 8 h; 100 µM temozolomide (TMZ) for 6 h; 
pretreatment with 40 µM DXM for 2 h followed by 100 µM 
TMZ for 6 h. (A) A representative gel picture showing level 
of expression of Bax. (B) A representative gel picture show-
ing level of expression of Bcl-2. (C) A representative gel pic-
ture showing level of expression of β-actin. (D) 
Densitometric analysis showing the Bax:Bcl-2 ratio in all 
treatment groups. Significant difference between CTL and 
TMZ treated cells was indicated by * (P ≤ 0.05) and significant 
difference between TMZ treated cells and DXM plus TMZ 
treated cells was indicated by # (P ≤ 0.05).Molecular Cancer 2004, 3:36 http://www.molecular-cancer.com/content/3/1/36
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mechanisms (Figs. 3, 4, 5, 6). Our data also suggested that
pretreatment with DXM can play a critical role in inhibit-
ing Ca2+ influx into the cells due to treatment with TMZ,
and thus preventing the progression of apoptotic process.
Several in vitro studies documented a role for calpain in
apoptosis of neuronal [30,31] as well as non-neuronal
cells [32]. However, the mechanisms of calpain mediated
cell death are not yet fully understood. Pro-apoptotic Bax
is translocated to mitochondria and has shown to be acti-
vated by calpain [33]. Increased expression of calpain con-
curs with elevated expression of Bax relative to Bcl-2,
suggesting that calpain overexpression plays an important
role during cell death [34,35]. Because changes in expres-
sion of pro-apoptotic Bax and anti-apoptotic Bcl-2 control
Determination of calpain and caspase-3 activities using West- ern blot analysis of α-spectrin breakdown products (SBDPs) Figure 5
Determination of calpain and caspase-3 activities 
using Western blot analysis of α-spectrin breakdown 
products (SBDPs). Four treatment groups: control (CTL); 
40 µM dexamethasone (DXM) for 8 h; 100 µM temozolo-
mide (TMZ) for 6 h; pretreatment with 40 µM DXM for 2 h 
followed by 100 µM TMZ for 6 h. (A) A representative gel 
picture showing generation of 145 kD and 120 kD SBDPs. 
(B) A representative gel picture showing level of expression 
of β-actin. (C) Densitometric analysis showing percent 
changes in optical density of the calpain-specific 145 kD 
SBDP over CTL. (D) Densitometric analysis showing percent 
change of optical density of the caspase-3-specific 120 kD 
SBDP over CTL. Significant difference between CTL and 
TMZ treated cells was indicated by * (P ≤ 0.05) and significant 
difference between TMZ treated cells and DXM plus TMZ 
treated cells was indicated by # (P ≤ 0.05).
Determination of caspase-3 activation using Western blot  analysis of caspase-3-p20 active band Figure 6
Determination of caspase-3 activation using Western 
blot analysis of caspase-3-p20 active band. Four treat-
ment groups: CTL; 40 µM DXM for 8 h; 100 µM TMZ for 6 
h; pretreatment with 40 µM DXM for 2 h followed by 100 
µM TMZ for 6 h. (A) A representative gel picture showing 
caspase-3 activation. (B) A representative gel picture showing 
level of expression of β-actin. (C) Densitometric analysis 
showing percent change in optical density of the caspase-3-
p20 active band over CTL. Significant difference between 
CTL and TMZ treated cells was indicated by * (P ≤ 0.05) and 
significant difference between TMZ treated cells and DXM 
plus TMZ treated cells was indicated by # (P ≤ 0.05).Molecular Cancer 2004, 3:36 http://www.molecular-cancer.com/content/3/1/36
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the mitochondrial pathway of apoptosis [14,15], we
examined the levels of expression of Bax and Bcl-2 pro-
teins in U87MG cells following treatment with TMZ (Fig.
4).
Our findings support a relationship between an increase
in intracellular free [Ca2+] (Fig. 3) and cell death with an
elevation of calpain activity (Fig. 5) following exposure of
U87MG cells to TMZ. Pretreatment of cells with DXM
showed a significant decrease in both intracellular free
[Ca2+] and calpain activity in a subsequent exposure to
TMZ. Increased intracellular free [Ca2+] causes activation
of calpain and degradation of cytoskeletal proteins [36]
with destabilization of the cellular integrity leading to cell
death [37]. Our results indicate that DXM plays an impor-
tant role in the prevention of calpain activation following
treatment of glioblastoma cells with TMZ. DXM has been
shown to inhibit apoptosis by induction of transcrip-
tional expression of anti-apoptotic proteins Bcl-2 and Bcl-
xL [37,38]. Upregulation of Bcl-2 either directly or indi-
rectly can repress the Ca2+ flux across the membrane of
endoplasmic reticulum, thereby abrogating apoptosis via
Ca2+ signaling [39].
Treatment of U87MG cells with TMZ caused increase in
calpain and caspase-3 activities as evidenced from the
cleavage of α-spectrin at specific sites generating 145 kD
SBDP and 120 kD SBDP, respectively (Fig 5). A pretreat-
ment with DXM decreased calpain and caspase-3 activities
in U87MG cells. Overall, the results from this investiga-
tion showed that DXM pretreatment interfered with
proteolytic activities and apoptotic death in U87MG cells
exposed to TMZ. A previous report from our laboratory
indicated that corticosteroids could inhibit the proteolytic
activity of calpain [40].
Our study suggests that pretreatment of glioblastoma with
DXM should be avoided if there is a plan to treat the
glioblastoma patients subsequently with TMZ. Some
recurrent glioblastomas remain resistant to almost all
current therapeutic endeavors, with low response rates
and survival rarely exceeding six months. As there are no
clearly established chemotherapeutic regimens for drug
resistant glioblastomas, obviously the only aim of therapy
is palliation with improvement in the quality of life. In
such cases, use of DXM or other glucocorticoids may not
be controversial. However, promising therapeutic activity
of TMZ against newly diagnosed anaplastic astrocytomas
and glioblastomas warrants continued evaluation of this
agent in combination settings [41]. Delaying disease pro-
gression by treatment with TMZ is beneficial to the
patients with recurrent glioblastomas [42]. Therefore, the
use of this drug should be explored further in an adjuvant
setting and in combination with other agents [43].
We showed that a pretreatment of human glioblastoma
U87MG cells with a low dose of DXM abolished the
chemotherapeutic action of TMZ (Figs. 1, 2, 3, 4, 5, 6),
raising a renewed concern about the validity of DXM as a
supportive therapy in the treatment of glioblastomas. We
acknowledge that pharmacological studies with a
glioblastoma cell line may not always yield results that are
easily transferred to the in vivo situation for cancer ther-
apy. Also, clinical recommendations should not be based
on in vitro data alone. Nevertheless, our data strongly sug-
gested that DXM treatment could well interfere with ther-
apeutic efficacy of chemotherapy in human glioblastoma
patients. In fact, this hypothesis is in line with the results
from a 1983 clinical trial where the combination of
bis(chloroethyl) nitrosourea (BCNU) plus high dose
methylprednisolone, a steroid, tended to be less effective
than BCNU alone in patients with poor prognosis [44].
The data reported here and the previous reports by others
[45], taken together, provide enough reason to call for
steroid withdrawal during investigative clinical trials of
chemotherapeutic agents in glioblastoma patients. This
should be a serious concern at the initial clinical situation
when glioblastoma patients are enrolled. In the case of
tumor progression during chemotherapy, steroids may
still be life-saving agents, and individual decisions con-
cerning a continuation of chemotherapy with concurrent
steroid treatment must be made. We also suggest limiting
steroid treatment in glioblastoma patients who are receiv-
ing chemotherapy outside a controlled clinical trial,
because the benefit of chemotherapy for glioblastoma
patients is still with limited efficacy and should not be fur-
ther compromised by co-medication with steroid. Further
investigations in xenografted and allografted animal
models of glioblastoma as well as in human glioblastoma
patients may shed new light in the controversial use of
DXM in palliation of human glioblastoma patients.
Materials and methods
Cell culture and treatments
Human glioblastoma U87MG cells were purchased from
the American Type Culture Collection (Manassas, VA).
Cells were grown in 75-cm2 flasks containing 10 ml of 1 ×
RPMI 1640 supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin and streptomycin in a fully-
humidified incubator containing 5% CO2 at 37°C. Prior
to drug treatments, the cells were starved in 1 × RPMI
1640 supplemented with 0.5% FBS for 24 h. Dose-
response studies were conducted to determine the suita-
ble doses of the drugs for using in the experiments. Cells
were pretreated with 40 µM DXM for 1 h. The DXM pre-
treated or untreated cells were subsequently treated with
100 µM TMZ for 6 h. Cells were washed with drug-free
medium and allowed to grow for 48 h. Then, cells were
collected for determination of viability, apoptosis, orMolecular Cancer 2004, 3:36 http://www.molecular-cancer.com/content/3/1/36
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Western blot analysis. DXM and TMZ were obtained from
Sigma Chemical (St. Louis, MO) and Schering Corpora-
tion (Kenilworth, NJ), respectively. The drugs were dis-
solved in dimethyl sulfoxide (DMSO) to make stock
solutions, which were then stored at -20°C until used for
treating cells.
Trypan blue dye exclusion test for cell viability
Following all treatments the viability of attached and
detached cell populations was evaluated by trypan blue
dye exclusion test [46]. Viable cells maintained mem-
brane integrity and did not take up trypan blue. Cells with
compromised cell membranes took up trypan blue, and
were counted as dead. At least 800 cells were counted in
four different fields and the number of viable cells was cal-
culated as percentage of the total cell population.
Wright staining for morphological analysis of apoptosis
The cells from each treatment were washed with PBS, pH
7.4, and sedimented onto the microscopic slides using
Cytobucket and Centra CL2 centrifuge (IEC) at 1200 rpm
for 5 min. Cells were fixed in 95% (v/v) ethanol before
examination of morphology with Wright staining [46].
The morphology of the apoptotic cells as detected by light
microscopy included such characteristic features as chro-
matin condensation, cell-volume shrinkage, and
membrane-bound apoptotic bodies. Four randomly
selected fields were counted for at least 800 cells. The per-
centage of apoptotic cells was calculated from three sepa-
rate experiments.
ApopTag assay for biochemical detection of apoptotic 
DNA fragmentation
ApopTag Peroxidase kit (Intergen, Purchase, NY) was used
to assess the extent of cell death following drug treat-
ments. Briefly, cells for each treatment were grown on six-
well cell culture plates (Corning Corporation., Corning,
NY) and were treated as described above. Following
treatments, cells were washed with PBS and then centri-
fuged to sediment onto the microscopic slides. Residual
PBS was then removed and cells were fixed using 95% (v/
v) ethanol and allowed to dry overnight. Slides were pre-
treated with a protein-digesting enzyme for 15 min and
then washed with distilled water for 2 min. Cells were
quenched with 3% (v/v) hydrogen peroxide for 5 min fol-
lowed by washing with PBS. Terminal deoxynucleotidyl
transferase (TdT) enzyme was added to the pre-equili-
brated cells and incubated for 1 h at 37°C. Stop-buffer
was added to the slide and agitated for 15 sec followed by
10 min incubation at room temperature. After washing
three times with PBS for 1 min each, anti-digoxigenin per-
oxidase conjugate was added to the slides and incubated
for 30 min. After slides were washed twice with PBS,
freshly prepared peroxidase substrate 3,3'-diaminobenzi-
dine was added to the slides and kept for 6 min and then
slides were washed with water two times. Slides were
counterstained with 0.5% (w/v) methyl green for 10 min
followed by washing with water and then 100% n-buta-
nol. After 10 min, cells were dehydrated in xylene for 2
min and then mounted with glass coverslip. Experiments
were conducted in triplicates and the percentage of
ApopTag-positive cells was determined by counting cells
under light microscopy.
Determination of intracellular free [Ca2+] using fura-2
We recently reported this method [47], which was modi-
fied for determination of intracellular free [Ca2+] in
U87MG cells. Briefly, cells were grown to 80% confluency
in phenol red-free medium for 72 h, suspended in the cul-
ture medium, centrifuged at 2000 rpm for 5 min to obtain
pellet, and washed twice in phosphate buffered saline
(PBS, pH 7.4). Cells were resuspended in culture medium,
and incubated at 37°C for 2 h with gentle shaking. Fol-
lowing incubation, cells wee washed twice in Ca2+-free
Locke's buffer [48] and then counted on a hemocytome-
ter. Cells (2 × 107 cells/ml) were dispersed in Locke's
buffer with 10% FBS. Fura-2 (Molecular Probes, Eugene,
OR) was dissolved in DMSO and diluted in Ca2+-free
Locke's buffer containing 10% FBS. Cells were mixed with
5 µM fura-2, incubated at 37°C for 30 min, washed twice
and diluted to 1 × 106 cells/ml in Ca2+-free Locke's buffer.
The intracellular free [Ca2+] was calculated spectrofluoro-
metrically using the equation [Ca2+] = Kdβ(R-Rmin)/(Rmax-
R), where β is the ratio of F380
max, fluorescence intensity
exciting at 380 nM for zero free Ca2+ to F380
min, and fluo-
rescence intensity at saturating free [Ca2+] as reported pre-
viously [49]. The determination of fluorescence ratio (R)
was performed using an SLM 8000 fluorometer (Ther-
mospectronic, Shelton, CT) at 340 and 380 nm wave-
lengths. The maximal (Rmax) and minimal (Rmin) ratios
were determined using 200 µl of 250 µM digitonin
(Sigma) and 500 mM EGTA (Sigma, St. Louis, MO),
respectively. The value of Kd, a cell-specific constant, was
determined experimentally to be 0.476 µM using stand-
ards of the Calcium Calibration Buffer Kit with Magne-
sium (Molecular Probes, Eugene, OR).
Antibodies
Monoclonal antibody against α-spectrin (Affiniti, Exeter,
UK) was used to measure calpain activity as well as cas-
pase-3 activity. Caspase-3 polyclonal antibody (MBL
International, Woburn, MA) was used to determine cas-
pase-3 activation. Bax and Bcl-2 monoclonal antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA) were used to
assess apoptotic threshold by determining the Bax:Bcl-2
ratio. Antibody to β-actin (monoclonal clone AC-15,
Sigma) was used to standardize protein loading in West-
ern blot experiments. The secondary antibody was horse-
radish peroxidase (HRP)-conjugated goat anti-mouse IgG
(ICN Biomedicals, Aurora, OH), except in case of calpainMolecular Cancer 2004, 3:36 http://www.molecular-cancer.com/content/3/1/36
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and  α-spectrin where HRP-conjugated goat anti-rabbit
IgG was used (ICN Biomedicals).
Western blotting and ECL detection
Cells were washed in culture flasks using Hank's balanced
salt solution without Ca2+ (GIBCO, Grand Island, NY).
The cells were then washed twice in phosphate buffered
saline (PBS, pH 7.4) and centrifuged in Eppendorf 5804R
(Brinkmann Instruments, Westbury, NY) at 106 × g for 10
min. Cells were resuspended in a homogenizing buffer
composed of 50 mM Tris-HCl (pH 7.4), 1 mM PMSF
(Bethesda Research Laboratories, Gaithersburg, MD), and
5 mM EGTA (Sigma). A polypropylene pestle (Kontes
Glass, Vineland, NJ) was placed inside the microcentri-
fuge tube (1.5 ml) containing cells and the tube was
placed inside an ice bucket for 2 min to let the pestle cool
to 4°C. Cells were completely homogenized for 30 sec
(the homogenization was performed while holding the
microcentrifuge tube in ice with one hand). Following
homogenization, protein concentration was determined
using Coomassie Plus Protein Assay Reagent (Pierce,
Rockford, IL) and spectrophotometric measurement at
595 nm (Spectronic, Rochester, NY). Samples were then
diluted (1:1) in sample buffer (62.5 mM, Tris pH 6.8, 2%
SDS, 5 mM β-mercaptoethanol, 10% glycerol) and boiled
for 5 min. Samples were then loaded onto the 4–20%
gradient gels for electrophoresis at 200 V for 30 min (Bio-
Rad, Hercules, CA). For detection of α-spectrin bands, a
5% gel was used for electrophoresis at 100 V for 2 h. Fol-
lowing electrophoresis, gels with the resolved proteins
were electroblotted to nylon membranes (Millipore,
Bedford, MA) in an electroblotting Genie apparatus (Idea
Scientific, Minneapolis, MN). The membranes were
blocked for 1 h in blocking buffer (5% powdered non-fat
milk, 20 mM Tris pH 7.6, 0.1% Tween 20 in saline). Pri-
mary antibody was diluted (1:100 for Bax, Bcl-2, caspase-
3, and 1:500 for calpain, 1:2,000 for α-spectrin, and
1:15,000 for β-actin) in blocking solution and then added
to the blots for 1 h. The blots were washed three times
with a wash buffer (Tris/Tween solution) and covered
with secondary antibody (goat anti-rabbit for calpain and
α-spectrin and goat anti-mouse for all others) at a 1:2000
dilution for 1 h. Blots were incubated with enhanced
chemiluminescence (ECL) detection system (Amersham
Pharmacia, Buckinghamshire, UK) and exposed to X-
OMAT AR films (Eastman Kodak, Rochester, NY). The
films were scanned on a UMAX PowerLook Scanner
(UMAX Technologies, Fremont, CA) using Photoshop
software (Adobe Systems, Seattle, WA), and optical den-
sity of each band was determined using Quantity One
software (Bio-Rad, Hercules, CA). Estimation of the deg-
radation products of α-spectrin indicated calpain and cas-
pase-3 activities. The 145 kD spectrin breakdown product
(SBDP) is specific for calpain activation [30], and the 120
kD SBDP is specific for caspase-3 activation [50]. Also,
Western blot analysis was performed to examine the gen-
eration of active 20 kD caspase-3 fragment from 32 kD
caspase-3, indicating activation of caspase-3.
Statistical analysis
Data from various experiments were analyzed using
StatView software (Abacus Concepts, Berkeley, CA).
Results were compared using one-way analysis of variance
(ANOVA) with Fisher's protected least significant differ-
ence (PLSD) post hoc test at a 95% confidence interval.
All results were presented as mean ± standard error of
mean (SEM) of separate experiments (n ≥ 3). A difference
between two values was considered significant at p ≤ 0.05.
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